Insilico Prodrug Designing of Some Matrix Metallo Proteinase Inhibitors Derived from Tanomastat

The present work describes the insilico prodrug designing of Tanomastat, a matrix metalloproteinase inhibitor. Tanomastat was selected as a lead and a series of prodrug-like molecules derived from it were generated. The pharmacokinetic and toxicity profile of these prodrug-like molecules was obtained by using ADME and TOX boxes web version of pharma Algorithms and ACD labs Chem Sketch software version 12.0. All prodrug-like molecules were predicted to be lipophilic, less toxic with an enhanced protein binding and better therapeutic efficacy. In conclusion, ADME and Toxicity properties of these molecules suggest advantages over Tanomastat.